Not every normotensive PE patient is truly low risk. sPESI helps identify patients who may be safe for outpatient management, while Bova helps recognize patients at risk for early deterioration despite initially stable vital signs.
In patients with intermediate-risk pulmonary embolism (PE), does ultrasound-facilitated, catheter-directed fibrinolysis (US-CDT) plus anticoagulation improve clinical outcomes compared to anticoagulation alone?
What are the differences in efficacy and safety of HFNC, NIPPV, and facemask oxygen for preoxygenation of patients who are critically ill requiring tracheal intubation?
The optimal treatment strategy for intermediate-risk (submassive) pulmonary embolism remains controversial. These patients are not in shock, but they have right ventricular (RV) dysfunction and myocardial injury, which are associated with higher risk for clinical decompensation and adverse outcomes.
The RENOVATE trial set out to answer a high-impact question across five distinct etiologic groups: Is HFNC non-inferior to BPAP (NIV) for preventing intubation or death in acute respiratory failure?
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
